Table 2.
mRNA vaccines against infectious diseases in clinic.
| Disease | Vaccine Name | Company | Route of Administration | Phase | Platform | Reference |
|---|---|---|---|---|---|---|
| mRNA-1273 | Moderna | IM | Approved | LNP | [148] | |
| BNT162b | Pfizer/BioNTech/Fosun Pharma | IM | Approved | LNP | [129] | |
| CVnCoV | CureVac | IM | IIb/III | LNP | NCT04652102 [149] | |
| SARS-CoV2 | LUNAR-COV19 | Arcturus Tx | IM | II | LNP | NCT04668339 |
| LNP-nCoVsaRNA | Imperial College London/VacEquity Global Health | IM | I | LNP | NCT04934111 | |
| ARCoV | Academy of Military Science/Walvax Biotech/Suzhou | IM | III | LNP | NCT04847102 | |
| ChulaCoV19 | Chulalongkorn University | IM | II | LNP | NCT04566276 | |
| Rabies | CV7201 | CureVac | IM | I | LNP | [150] |
| CV7202 | CureVac | IM | I | LNP | [151] | |
| Influenza | mRNA-H10N8, mRNA-H7N9 | Moderna | IM | I | LNP | [152] |
| Respiratory syncytial virus (RSV) | mRNA-1345 | Moderna | IM | I | LNP | NCT04528719 |
| Human metapneumovirus (HMPV) and parainfluenza virus type 3 (PIV3) | mRNA-1653 | Moderna | IM | Ib | LNP | NCT04144348 NCT03392389 |
| Human Cytomegalovirus (HCMV) | mRNA-1647 | Moderna | IM | III | LNP | NCT05085366 |
| Zika virus | mRNA-1893 | Moderna | IM | II | LNP | NCT04917861 |